ABCG2-Rich Extracellular Vesicles and Multidrug Resistance in Cancer
Author Information
Author(s): Goler-Baron Vicky, Assaraf Yehuda G.
Primary Institution: The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel
Hypothesis
Can extracellular vesicles (EVs) mediate multidrug resistance (MDR) in cancer cells through the concentration of anticancer drugs?
Conclusion
The study identifies a novel mechanism of drug resistance in cancer cells where ABCG2-rich extracellular vesicles sequester multiple anticancer drugs, leading to increased resistance.
Supporting Evidence
- ABCG2-rich EVs can concentrate anticancer drugs like topotecan and methotrexate, leading to drug resistance.
- EVs are structurally similar to bile canaliculi and are formed by the interaction of multiple cancer cells.
- Tight junction proteins like occludin and ZO-1 are involved in the formation of sealed EVs.
Takeaway
Cancer cells can create tiny bubbles called extracellular vesicles that trap medicine, making it harder for the medicine to work. This helps the cancer survive even when treated.
Methodology
The study used immunofluorescence microscopy to analyze the localization of ABC transporters in EVs and assessed drug accumulation in these vesicles.
Limitations
The study primarily focuses on specific cancer cell lines and may not generalize to all types of cancer or other cell types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website